ARNUITY ELLIPTA Drug Patent Profile

Which patents cover Arnuity Ellipta, and what generic alternatives are available?

Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.

Summary for ARNUITY ELLIPTA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	2
Patent Applications:	1,566
Drug Prices:	Drug price information for ARNUITY ELLIPTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARNUITY ELLIPTA
What excipients (inactive ingredients) are in ARNUITY ELLIPTA?	ARNUITY ELLIPTA excipients list
DailyMed Link:	ARNUITY ELLIPTA at DailyMed

See drug prices for ARNUITY ELLIPTA

Recent Clinical Trials for ARNUITY ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Virginia	Phase 2
GlaxoSmithKline	Phase 3

See all ARNUITY ELLIPTA clinical trials

Pharmacology for ARNUITY ELLIPTA

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ARNUITY ELLIPTA

ARNUITY ELLIPTA is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014		RX	Yes	Yes
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes

Expired US Patents for ARNUITY ELLIPTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014

EU/EMA Drug Approvals for ARNUITY ELLIPTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline (Ireland) Limited	Avamys	fluticasone furoate	EMEA/H/C/000770Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.	Authorised	no	no	no	2008-01-11
Glaxo Group Ltd.	Alisade	fluticasone furoate	EMEA/H/C/001019Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.	Withdrawn	no	no	no	2008-10-06

International Patents for ARNUITY ELLIPTA

See the table below for patents covering ARNUITY ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	310	Inhalation device.
African Regional IP Organization (ARIPO)	9100321
Austria	401007
Austria	A43791
Australia	5926794
Australia	645056
Australia	675825

Supplementary Protection Certificates for ARNUITY ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	91429	Luxembourg		91429, EXPIRES: 20230111
1305329	CA 2008 00022	Denmark
1305329	300343	Netherlands		300343, 20210803, EXPIRES: 20230110
1305329	SPC011/2008	Ireland		SPC011/2008: 20081105, EXPIRES: 20230110
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1305329	C01305329/01	Switzerland		PRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116

ARNUITY ELLIPTA (fluticasone furoate) market dynamics and financial trajectory: sales trends, payer environment, generic and exclusivity timeline, and key drivers

Last updated: July 24, 2026

What drives ARNUITY ELLIPTA sales growth or decline in the US inhaled corticosteroid market?

ARNUITY ELLIPTA is a once-daily inhaled corticosteroid (ICS) for asthma maintenance. Its US market performance tracks three variables: formulary placement versus competing ICS/LABA and ICS, net price after rebates, and share stability in the ELLIPTA channel versus rival delivery systems.

What is the competitive set ARNUITY ELLIPTA competes against?

The commercial head-to-head is not only versus other ICS products, but also versus inhaler brands that win “preferred” status through payer contracting and patient adherence benefits.

Key comparators:

• ICS + LABA fixed-dose combinations (often preferred over ICS alone as guideline-based step therapy advances)
• Other once-daily ICS and non-daily or twice-daily competitors depending on the payer’s formulary tiering
• Dry powder inhaler (DPI) platform competitors with similar dosing convenience
• Nebulized steroid approaches in sub-populations, mainly limited by device preference and coverage

How do net price and rebates affect the financial trajectory?

ARNUITY ELLIPTA revenue reported in public sources is sensitive to:

• rebate intensity and step-edits
• copay card economics and payer clawbacks
• mix shift toward lower tier formularies in certain geographies
• channel inventory turns for DPI devices, which affect short-term sell-through

What patient and prescriber factors influence utilization?

• Once-daily dosing supports adherence, often stabilizing prescription continuity versus twice-daily ICS regimens.
• Real-world switching: patients can move to ICS/LABA once asthma control is suboptimal, compressing long-term ICS-only growth.
• ELLIPTA ecosystem effects: prescriber familiarity with the device and cross-brand switching can either support share or be diluted when alternative DPI options gain tier placement.

How many years of exclusivity protect ARNUITY ELLIPTA and when does it face generic entry risk?

Exclusivity and generic entry are driven by the patent estate tied to fluticasone furoate’s approved dosage form, device and method claims, plus any remaining regulatory exclusivities attached to the underlying application.

When does ARNUITY ELLIPTA lose exclusivity?

The decisive commercial timing issue is when the last relevant US patent covering eligible claims expires or is successfully challenged, since generics can enter once they can lawfully make and sell a product meeting label and exclusivity requirements. For market impact, the practical trigger is:

• Orange Book patent expiration date(s) for formulation/device/method claims (not just marketing exclusivity)
• launch-after-expiration windows for ANDA filers and any settlement-triggered carve-outs

What generic entry risks exist for ARNUITY ELLIPTA?

Generic risk is concentrated in:

• ANDA timing relative to patent expirations
• whether the ANDA includes Paragraph IV challenges on key listed patents
• the scope of any final injunction or settlement that delays launch or narrows authorized product strength
• potential skinny-label opportunities if remaining claims cover narrower indications, strength(s), or device-related features

What is the Orange Book status of ARNUITY ELLIPTA and how does it map to patent expiration?

A reliable market-dynamics view depends on the Orange Book listing for the specific strengths and dosage forms: ARNUITY ELLIPTA includes multiple strength presentations. Patent coverage can differ by strength, formulation, and claim scope.

How many Orange Book-listed patents typically matter for inhaled corticosteroid products?

For inhaled products, the patents that drive generic risk typically include:

• formulation compositions (particle engineering, excipients, drug substance interactions)
• methods of manufacture
• device-related claims or delivery performance targets
• process claims tied to the DPI formulation and filling steps

Patent estate mapping to commercial risk

Commercial impact concentrates on the last expiring:

• composition or formulation claims that prevent “same formulation” workarounds
• process claims that can delay manufacturability and validation for generic filers
• method-of-use claims if they cover asthma management aspects beyond the core maintenance label

Which companies are challenging ARNUITY ELLIPTA with Paragraph IV ANDAs?

Patent litigation and Paragraph IV filings are the next-layer timing mechanism that determines launch dates and settlement outcomes, which in turn drive revenue step-down.

How do Paragraph IV challenges affect the financial trajectory?

• a successful challenge can lead to a launch at or soon after patent expiry
• a settlement can shift launch to a later date or carve out certain strengths/dosages
• litigation outcomes can also reduce market supply availability, keeping branded share higher for longer

What ARNUITY ELLIPTA litigation affects revenue, settlements, or injunctions?

For a brand with an entrenched inhaler franchise, the key revenue inflection points come from:

• injunctions that delay generic launch post-challenge
• “design-around” efforts that preserve brand control but create replacement competitors
• settlements that set clear authorized entry dates, often with multi-strength sequencing

How to interpret litigation signals for investor planning

• If multiple patents are asserted, the settlement or final court rulings typically determine how quickly the first generic can ship.
• If the asserted patents include formulation and method claims, courts often focus on infringement and obviousness of specific manufacturing approaches, increasing the risk that generic timelines compress only after deeper legal resolution.

What is ARNUITY ELLIPTA revenue trajectory versus peers, and where is the margin pressure coming from?

To interpret financial trajectory, market observers usually compare:

• branded sell-in and sell-through trends
• net sales decline versus generic erosion timing
• SG&A and promotional spending intensity
• payer mix and rebate leverage

Revenue trajectory patterns typical for ICS inhalers

• stable growth early in franchise life, followed by plateau as competing combinations gain preferred tiering
• episodic step-down when generics enter (if applicable for each strength)
• recurring decline when broader asthma control regimens shift toward ICS/LABA for step-up patients

Margin drivers

• rebate intensity compresses gross-to-net
• contracting can pressure wholesale acquisition cost
• device platform costs and supply lead times matter for inhaler brands, especially when competitors introduce price pressure after entry

How does ARNUITY ELLIPTA compare with BREO ELLIPTA and other ICS/LABA products on market dynamics?

ARNUITY ELLIPTA is positioned as an ICS maintenance option. Its key commercial constraint is that many patients step up to combination therapy for better control.

What “switching” does the market show?

• Patients with frequent exacerbations or poor symptom control often migrate from ICS-only to ICS/LABA.
• Prescribers using once-daily convenience may prefer combination inhalers when formularies push toward preferred ICS/LABA.

How delivery platform affects share

The ELLIPTA platform can create cross-brand adherence benefits and inhaler familiarity, but payer tiering determines which product wins. When combination therapy is preferred, ARNUITY ELLIPTA often faces share compression even if adherence remains strong.

What formulation and dosing factors protect ARNUITY ELLIPTA from copycats?

Generic entry for inhalers often hinges on formulation equivalence and manufacturing reproducibility, but the practical business question is whether protected formulation aspects block a sufficiently similar product.

Which patent categories most often protect inhaled corticosteroid products?

• particle engineering and spray characteristics
• excipient selection influencing aerosolization
• manufacturing process steps that control particle properties
• DPI performance and device integration claims

What does “strength” mean for IP and launch sequencing?

Inhaled corticosteroid products often have multiple strengths. Patent scope and infringement theories can differ by strength, which can lead to:

• first generic launch at one strength with later entries for other strengths
• litigation that delays one strength longer due to device/formulation differences

What generic launch scenario best explains post-entry market share erosion for inhalers?

When generics launch, erosion for inhaler brands usually reflects:

• formulary substitution and step therapy changes by PBMs
• patient assistance program discontinuities or restrictions
• switching driven by pharmacy claims and copay differences

What share losses typically follow first ANDA launches?

• first generic entry can cause a fast drop in prescription fills even without immediate full price collapse, because PBMs often narrow tier options
• subsequent competitors accelerate erosion via contracting leverage and multiple-source pricing

Key takeaways

• ARNUITY ELLIPTA’s financial trajectory is driven by net price versus rebates, formulary tiering versus ICS/LABA alternatives, and adherence stability from once-daily dosing.
• Generic entry risk depends on the remaining US patent estate listed for fluticasone furoate DPI strengths and the outcomes of any Paragraph IV challenges and settlements.
• Litigation timing determines whether revenue declines in a single step (early launch) or in staged waves (strength-by-strength).
• Cross-inhaler switching toward combination therapy is the core long-term headwind for ICS-only maintenance brands.

FAQs

1) What is ARNUITY ELLIPTA used for in asthma treatment?

ARNUITY ELLIPTA is an inhaled corticosteroid indicated for maintenance treatment of asthma in appropriate patient populations.

2) Does ARNUITY ELLIPTA have multiple strengths that can enter generically at different times?

Inhaled corticosteroid products often have strength-dependent patent and launch timelines, with generic entry sometimes occurring in stages.

3) How do payer formularies typically treat ICS-only products versus ICS/LABA?

PBMs often prefer combination products as patients step up in asthma control, which can compress ICS-only share.

4) What matters more for inhaler generic timelines: marketing exclusivity or Orange Book patents?

Orange Book patent expiration and patent-challenge outcomes control lawful launch timing.

5) Do settlements affect brand revenue even after patent expiry?

Yes. Settlement terms often set specific authorized entry dates and can delay launch beyond the earliest patent expiry.

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). US Food and Drug Administration.
2. FDA. Drug Trials Snapshots: ARNUITY ELLIPTA (fluticasone furoate) (as applicable). US Food and Drug Administration.
3. FDA. Prescription Drug User Fee Act and drug labeling database for ARNUITY ELLIPTA (as applicable). US Food and Drug Administration.
4. Company financial disclosures and investor materials for relevant reporting periods (as applicable).
5. Public patent and litigation dockets referencing ARNUITY ELLIPTA Orange Book listed patents (as applicable).